LAS VEGAS, April 11, 2019 /PRNewswire/ -- Global spending on cancer therapies and supportive care drugs now exceeds USD 133 billion in 2017, and this amount is projected to reach USD 180-200 billion over the next five years.
About 4,000 patients are treated with Provenge each year in the US out of a possible 40,000 in 2018 currently. Out of three, Oncorine and Imlygic are the oncolytic virus-based gene therapies. Imlygic is the first oncolytic virus-based gene therapy to get approval in the US and Europe.
Almost, three decades after the first gene therapy trial, the approved gene therapies are only three in Europe and those are:-
Glybera (alipogene tiparvovec)
Imlygic (talimogene laherparepvec)
Strimvelis (autologous CD34+ cells transduced to express ADA)
"Around 70% of the global clinical trials are running in the US, making it a most lucrative market for gene therapy in oncology."
The pipeline of gene therapy in cancer appears to be very strong with total of 47 products in development. Phase II & Phase I/II phase gene therapies grab 43% of the total clinical product share in 2018.
The company product analysis shows that majority of the products with the company have already made it to the clinical with around 64% of the products. Also, there are 36% products in Phase 1 ready, pre-clinical and discovery stages.
Overall in gene therapy oncology, around 23% of the products are partnered, and about 77% of products are non-partnered. The non-partnered products offer excellent investment opportunities for companies seeking a partnership in gene therapy in Oncology.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.